Benzinga's Daily Biotech Pulse: Biogen And Eisai's Alzheimer's Drug Meets End Points In Mid-Stage Trial, Obseva To List Shares On Swiss Exchange

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling the Peaks

(Stocks hitting 52-week highs on July 5)

• Arbutus Biopharma Corp ABUS
• Endocyte, Inc. ECYT
• Merus NV MRUS
• Orthopediatrics Corp KIDS(Piper Jaffray raised price target from $24 to $30)
• Repligen Corporation RGEN

Down In The Dumps

(Stocks hitting 52-week lows on July 3)

• Iterum Therapeutics PLC ITRM
• Reshape Lifesciences Inc RSLS
• RXi Pharmaceuticals Corp RXII
• Sol Gel Technologies Ltd SLGL
• THERAPIX BIOSCI/S ADR TRPX
• Related Link: Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

Stocks In Focus

Biogen-Eisai's Alzheimer's Drug Meets Predefined End Points In Mid-stage Trial

Biogen Inc BIIB and Eisai announced positive topline results from the Phase 2 study of their BAN2401, which was evaluated in a 856-patient trial for treating early Alzheimer's disease.

BAN2401 is an anti-amyloid beta protofibril antibody.

"The study achieved statistical significance on key predefined endpoints evaluating efficacy at 18 months on slowing progression in Alzheimer's Disease Composite Score (ADCOMS) and on reduction of amyloid accumulated in the brain as measured using amyloid-PET (positron emission tomography)," the companies said.

Obseva To List Shares On Swiss Exchange

Obseva SA OBSV announced its shares will be listed on the SIX Swiss Exchange, effective July 13 under the ticker symbol OBSN. The company shares are already listed on the Nasdaq since Jan. 2017. Obseva also indicated that it will not issue any additional shares related to its Swiss listing.